Page 219 - Remedial Andrology

1006. Habous, M., et al. Outcomes of variation in technique and variation in accuracy of measurement in
penile length measurement. Int Impot Res, 2018. 30: 21.
https://pubmed.ncbi.nlm.nih.gov/29180797
1007. Levine, L.A., et al. Establishing a standardized evaluation of the man with Peyronie’s disease. Int
J Impot Res, 2003. 15 Suppl 5: S103.
https://pubmed.ncbi.nlm.nih.gov/14551586
1008. Ozmez, A., et al. The Effectiveness of 3-D Computed Tomography in the Evaluation of Penile
Deformities in Patients With Peyronie’s Disease: A Pilot Study. Sex Med, 2019. 7: 311.
https://pubmed.ncbi.nlm.nih.gov/31324507
1009. Hauck, E.W., et al. Diagnostic value of magnetic resonance imaging in Peyronie’s disease--a
comparison both with palpation and ultrasound in the evaluation of plaque formation. Eur Urol,
2003. 43: 293.
https://pubmed.ncbi.nlm.nih.gov/12600434
1010. Nguyen, H.M.T., et al. Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment
of Acute-Phase Peyronie’s Disease. J Sex Med, 2017. 14: 1220.
https://pubmed.ncbi.nlm.nih.gov/28874331
1011. Gholami, S.S., et al. Peyronie’s disease: a review. J Urol, 2003. 169: 1234.
https://pubmed.ncbi.nlm.nih.gov/12629334
1012. Kadioglu, A., et al. Color Doppler ultrasound assessment of penile vascular system in men with
Peyronie’s disease. Int J Impot Res, 2000. 12: 263.
https://pubmed.ncbi.nlm.nih.gov/11424963
1013. Dean, R.C., et al. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol
Clin North Am, 2005. 32: 379.
https://pubmed.ncbi.nlm.nih.gov/16291031
1014. McCauley, J.F., et al. Diagnostic utility of penile ultrasound in Peyronie’s disease. World J Urol, 2020.
38: 263.
https://pubmed.ncbi.nlm.nih.gov/31606787
1015. Porst, H., et al. Standards for clinical trials in male sexual dysfunctions. J Sex Med, 2010. 7: 414.
https://pubmed.ncbi.nlm.nih.gov/20092447
1016. Muller, A., et al. Peyronie’s disease intervention trials: methodological challenges and issues. J Sex
Med, 2009. 6: 848.
https://pubmed.ncbi.nlm.nih.gov/19138374
1017. Nehra, A., et al. Peyronie’s Disease: AUA Guideline. J Urol, 2015. 194: 745.
https://pubmed.ncbi.nlm.nih.gov/26066402
1018. Bella, A.J., et al. 2018 Canadian Urological Association guideline for Peyronie’s disease and
congenital penile curvature. Can Urol Assoc J, 2018. 12: E197.
https://pubmed.ncbi.nlm.nih.gov/29792593
1019. Dahm, P., et al. Moving from Consensus- to Evidence-Based Clinical Practice Guidelines for
Peyronie’s Disease. J Sex Med, 2017. 14: 170.
https://pubmed.ncbi.nlm.nih.gov/28065352
1020. Safarinejad, M.R., et al. A double-blind placebo-controlled study of the efficacy and safety of
pentoxifylline in early chronic Peyronie’s disease. BJU Int, 2010. 106: 240.
https://pubmed.ncbi.nlm.nih.gov/19863517
1021. Safarinejad, M.R., et al. Retraction statement: A double-blind placebo-controlled study of the
efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int, 2015. 115: E10.
https://pubmed.ncbi.nlm.nih.gov/25830185
1022. Ferrini, M.G., et al. Effects of long-term vardenafil treatment on the development of fibrotic plaques
in a rat model of Peyronie’s disease. BJU Int, 2006. 97: 625.
https://pubmed.ncbi.nlm.nih.gov/16469038
1023. Valente, E.G., et al. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the
Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide, 2003. 9: 229.
https://pubmed.ncbi.nlm.nih.gov/14996430
1024. Ilg, M.M., et al. Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators
Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie’s Disease. J Sex Med, 2020.
17: 1848.
https://pubmed.ncbi.nlm.nih.gov/32771352
1025. Chung, E., et al. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical
and radiological outcomes. J Sex Med, 2011. 8: 1472.
https://pubmed.ncbi.nlm.nih.gov/21324095

218 SEXUAL AND REPRODUCTIVE HEALTH - MARCH 2021